Sex-specific hormone changes during immunotherapy and its influence on survival in metastatic renal cell carcinoma.
Checkpoint inhibition
Estrogen
Immunotherapy
Luteinizing hormone/follicle-stimulating hormone
Renal cell carcinoma
Sex hormones
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
24
07
2020
accepted:
01
02
2021
pubmed:
2
3
2021
medline:
30
9
2021
entrez:
1
3
2021
Statut:
ppublish
Résumé
Renal cell carcinoma (RCC) is a highly vascularized and immunogenic tumor, being an ideal candidate for checkpoint blockade-based immunotherapy. Accordingly, checkpoint inhibitors have demonstrated clinical efficacy in patients with metastatic RCC (mRCC). Sex-specific differences in cancer immunotherapy may be explained by the interaction of sex hormone signaling, genetic and environmental factors, affecting the innate and adaptive immune response in men and women in different ways. The aim of this prospective study was to monitor for the first time changes in sex hormones including luteinizing hormone (LH), follicle-stimulating hormone (FSH), LH/FSH ratio and 17-ß-estradiol (E2) in 22 mRCC patients (12 male and 10 female) receiving nivolumab therapy. In contrast to female patients, male patients showed a significant increase in E2 (p = 0.006) and LH/FSH ratio (p = 0.013) from the beginning of nivolumab therapy to week 12 of follow-up. Moreover, survival analysis revealed a significant negative association between LH/FSH ratio and progression-free survival (PFS) (p = 0.022) as well as between therapy response (p = 0.009) in males compared to females at interim evaluation (week 6/8). Our findings may therefore be the first reference to sex hormone changes during immunotherapy.
Identifiants
pubmed: 33646368
doi: 10.1007/s00262-021-02882-y
pii: 10.1007/s00262-021-02882-y
pmc: PMC8423679
doi:
Substances chimiques
Gonadal Steroid Hormones
0
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2805-2817Subventions
Organisme : Medical Research Foundation Tyrol
ID : 297
Informations de copyright
© 2021. The Author(s).
Références
Eur Urol. 2009 Jun;55(6):1333-42
pubmed: 19201522
Lung Cancer. 2011 Nov;74(2):318-25
pubmed: 21511357
JAMA Netw Open. 2020 Aug 3;3(8):e2012534
pubmed: 32766800
Eur Urol. 2017 Dec;72(6):962-971
pubmed: 28262413
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Cancer Res. 1978 Nov;38(11 Pt 2):4340-4
pubmed: 698974
J Neurosci Res. 2006 Aug 1;84(2):370-8
pubmed: 16676326
JAMA Oncol. 2019 Apr 1;5(4):529-536
pubmed: 30605213
PLoS One. 2015 Oct 15;10(10):e0140817
pubmed: 26469346
Cancer Immunol Immunother. 2007 Jun;56(6):897-903
pubmed: 17106716
Eur Urol. 2018 Dec;74(6):e139-e140
pubmed: 30031571
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Ann Oncol. 2018 Nov 1;29(11):2208-2213
pubmed: 30215677
Clin Exp Immunol. 1996 Nov;106(2):410-5
pubmed: 8918592
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Clin Cancer Res. 2019 Aug 1;25(15):4603-4610
pubmed: 30890551
Cancer. 2007 Dec 1;110(11):2468-77
pubmed: 17932908
J Exp Med. 2005 Jul 18;202(2):231-7
pubmed: 16027236
Cancer Immunol Immunother. 2012 Sep;61(9):1407-13
pubmed: 22278360
Int Rev Immunol. 2015 Mar;34(2):134-42
pubmed: 25901858
Clin Microbiol Rev. 2001 Jul;14(3):476-88
pubmed: 11432809
Front Endocrinol (Lausanne). 2020 Feb 25;11:72
pubmed: 32158430
J Clin Oncol. 2009 Dec 1;27(34):5794-9
pubmed: 19826129
Cancer Res. 2018 Sep 1;78(17):5011-5022
pubmed: 29967259
Clin Cancer Res. 2008 Jul 15;14(14):4417-26
pubmed: 18579664
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Immunology. 2009 Mar;126(3):329-35
pubmed: 19302141
J Clin Oncol. 2006 Feb 20;24(6):898-903
pubmed: 16484699
Cancer Res. 1997 Apr 15;57(8):1537-46
pubmed: 9108457
ESMO Open. 2018 Apr 13;3(3):e000344
pubmed: 29682332
Nat Rev Immunol. 2016 Oct;16(10):626-38
pubmed: 27546235
Lancet. 1998 Oct 24;352(9137):1358
pubmed: 9802280
J Clin Oncol. 2015 Jun 20;33(18):2013-20
pubmed: 25800770
Lancet Oncol. 2018 Jun;19(6):737-746
pubmed: 29778737
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
Breast Cancer Res. 2002;4(2):65-9
pubmed: 11879566
Mol Oncol. 2018 Dec;12(12):2055-2071
pubmed: 30171816
J Clin Endocrinol Metab. 2000 Sep;85(9):3027-35
pubmed: 10999781
J Natl Cancer Inst. 1993 Apr 21;85(8):622-32
pubmed: 8468720
Lancet Oncol. 2016 Jul;17(7):994-1003
pubmed: 27283863
Curr Drug Targets Inflamm Allergy. 2004 Mar;3(1):97-104
pubmed: 15032646
Am J Reprod Immunol. 2016 Aug;76(2):118-25
pubmed: 27321759
Br J Cancer. 2007 Mar 12;96(5):845-9
pubmed: 17311018
Oncotarget. 2017 Nov 1;8(59):99336-99346
pubmed: 29245905
J Clin Oncol. 2003 Aug 15;21(16):3127-32
pubmed: 12915604
PLoS One. 2013;8(2):e56667
pubmed: 23460808
Molecules. 2019 Sep 04;24(18):
pubmed: 31487832
Br J Cancer. 2017 Apr 25;116(9):1141-1147
pubmed: 28324889
J Clin Oncol. 2002 Jan 1;20(1):289-96
pubmed: 11773181
Int Immunopharmacol. 2001 Jun;1(6):983-93
pubmed: 11407317
Sci Rep. 2015 Mar 17;5:9160
pubmed: 25779055
Lancet Oncol. 2019 Oct;20(10):1370-1385
pubmed: 31427204
Semin Oncol. 1983 Dec;10(4):422-30
pubmed: 6320451
Onco Targets Ther. 2018 Sep 17;11:5873-5878
pubmed: 30271170
Int J Gynecol Cancer. 2017 Feb;27(2):196-205
pubmed: 27870715